Gilead Sciences   4Q Revenues: $1.1 billion (+22%) 4Q Earnings: $401.6 million (loss of $1.7 billion in 4Q06)* FY Revenues: $4.2 billion (+40%) FY Earnings: $1.6 billion (loss of $1.2 billion FY06)* Comments: Product sales were a record $1 billion for the quarter (+34%), driven by HIV product franchise and the growth of Atripla and Truvada. HIV product sales were $864.2 million in the quarter (+35%) and $3.1 billion for the year (+48%). Truvada sales were up 33% in the quarter and ...